Biotechnology company BriaCell Therapeutics Corp. (BCTX, BCT.V) announced Wednesday positive overall survival data of its Phase 2 clinical study of Bria-IMT in combination with an immune check point inhibitor (CPI) in late stage metastatic breast cancer.The median overall survival of 15.6 months is reported in Phase 2 Bria-IMT study patients treated in combination with immune checkpoint inhibitor.

生物技术公司BriaCell Therapeutics Corp.（BCTX，BCT.V）周三宣布，其Bria IMT联合免疫检查点抑制剂（CPI）治疗晚期转移性乳腺癌的2期临床研究的总体生存率为阳性。据报道，与免疫检查点抑制剂联合治疗的2期Bria IMT研究患者的中位总生存期为15.6个月。

The OS of 15.6 months compares favorably with 6.7-9.3 months reported for similar patients in the literature.These patients are being treated with the same Bria-IMT formulation currently being used in BriaCell's ongoing Phase 3 pivotal study in metastatic breast cancer.This represents a substantial improvement over BriaCell's 13.4 months median OS previously reported in December 2023..

15.6个月的OS与文献中类似患者报告的6.7-9.3个月相比有利。这些患者正在接受与BriaCell正在进行的转移性乳腺癌3期关键研究中使用的Bria IMT制剂相同的治疗。这比BriaCell之前在2023年12月报告的13.4个月的中位操作系统有了实质性的改进。。

The Phase 2 study enrolled 54 heavily pre-treated metastatic breast cancer patients who were treated with the Bria-IMT regimen and an immune checkpoint inhibitor. Of these 54 patients, 37 were treated with the Phase 3 formulation and 25 of these were treated post-COVID when full study activities resumed.This data represents an additional six months of follow-up of the survival data presented at the San Antonio Breast Cancer Symposium in December 2023.

第二阶段研究招募了54名接受Bria IMT方案和免疫检查点抑制剂治疗的重度预处理转移性乳腺癌患者。在这54名患者中，37名接受了3期制剂治疗，其中25名在全面研究活动恢复后接受了新型冠状病毒治疗。这些数据代表了2023年12月圣安东尼奥乳腺癌研讨会上提出的生存数据的另外六个月的随访。